Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23970861 | 0.83 | CYP3A4 (0.39) | HSP90AA1HSP90AB1TRPA1CYP3A4CYP2D6 | |
| SCHEMBL13086672 | 0.82 | PDE2A (0.42) | LMNACYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL19105584 | 0.80 | NOTUM (0.37) | TRPA1CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL24910219 | 0.80 | PDE2A (0.37) | TRPA1CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL19105630 | 0.80 | CYP3A4 (0.37) | HSP90AA1HSP90AB1LMNATRPA1CYP3A4 | |
| SCHEMBL25165502 | 0.78 | SCN10A (0.37) | TRPA1CYP3A4CYP2D6TSHRCRHBP | |
| SCHEMBL24850231 | 0.78 | USP1 (0.37) | HSP90AA1HSP90AB1LMNATRPA1CYP3A4 | |
| SCHEMBL17703498 | 0.78 | TRPV4 (0.38) | HSP90AA1HSP90AB1LMNACYP3A4CYP2D6 | |
| SCHEMBL21625521 | 0.77 | CA2 (0.41) | HSP90AA1HSP90AB1CYP3A4CYP2D6TSHR | |
| SCHEMBL12263473 | 0.77 | PDE2A (0.35) | LMNACYP3A4CYP2D6TSHRCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3712144-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | HSP90AA1 3034/4885HSP90AB1 2757/4885LMNA 1680/4885 |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | HSP90AA1 360/4885HSP90AB1 395/4885LMNA 691/4885 |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | HSP90AA1 3076/4885HSP90AB1 2771/4885LMNA 2224/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | HSP90AA1 723/4885HSP90AB1 672/4885LMNA 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.